News
After Earthquakes, Adult Day Centers Play Valuable Role for Elderly
- Author:
- Neil Osterweil
News
After Earthquakes, Adult Day Centers Play Valuable Role for Elderly
- Author:
- Neil Osterweil
News
After Earthquakes, Adult Day Centers Play Valuable Role for Elderly
- Author:
- Neil Osterweil
News
Problem-Solving Therapy Eases Depression in Elderly
- Author:
- Neil Osterweil
News
Problem-Solving Therapy Eases Depression in Elderly
- Author:
- Neil Osterweil
News
Problem-Solving Therapy Eases Depression in Elderly
- Author:
- Neil Osterweil
News
Universal MRSA Screening at L&D: Little Benefit
- Author:
- Neil Osterweil
News
Despite Setbacks, Therapeutic Cancer Vaccine Trials March On
- Author:
- Neil Osterweil
News
Rituximab Improves Survival in CD20+ B-Lineage ALL
- Author:
- Neil Osterweil
Major Finding: In standard-risk patients with B-lineage CD20+ acute lymphoblastic leukemia, the addition of rituximab improved the continuous 5-...
News
No Increased Cancer Risk Seen in Stem Cell, Marrow Donors
- Author:
- Neil Osterweil
Major Finding: The standard incidence ratio for all malignancies among all donors was 0.99.Data Source: Survey based on 55,228 observation-years...
News
Liposomal Cytarabine-Daunorubicin Improves AML Remission Rates
- Author:
- Neil Osterweil
Major Finding: Novel CPX-351 was associated with significantly better overall survival in a subgroup of patients with secondary AML (median, 12.1...
News
Romidepsin Induces Complete Response in Peripheral T-Cell Lymphoma
- Author:
- Neil Osterweil
Major Finding: Romidepsin was associated with a 13% complete response rate in patients with peripheral T-cell lymphoma that had relapsed or was...
News
R-ACVBP Gives Survival Edge Over R-CHOP in Patients With DLBCL
- Author:
- Neil Osterweil
Major Finding: Among patients younger than age 60 who had diffuse large B-cell lymphoma, the 3-year overall survival rates were 92% for those...
News
VRD Plus Lenalidomide Maintenance Yields Good Results in Myeloma
- Author:
- Neil Osterweil
Major Finding: 84% of patients with previously untreated multiple myeloma had a very good partial response or better following induction,...
News
Subcutaneous Bortezomib in Myeloma Matches IV For Efficacy, Has Better Safety Profile
- Author:
- Neil Osterweil